Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice.

"Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Omid C. Farokhzad has financial interest in Selecta Biosciences, Tarveda Therapeutics, and Seer."

"This work was supported in part by the 10.13039/100000892Prostate Cancer Foundation (PCF) Young Investigator Award (J.S.), the David Koch-PCF Award in Nanotherapeutics (O.C.F.), and the US 10.13039/100000002National Institutes of Health (10.13039/100000002NIH) grant CA200900 (J.S. and B.R.Z.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. O.C.F. has financial interests in Selecta Biosciences, Tarveda Therapeutics, and Seer."